机构：[1]Department of Urology, Institute of Science Tokyo, Tokyo, Japan.[2]Department of Urology, Zigong Fourth People's Hospital, Zigong, Sichuan, China.
For metastatic hormone-sensitive prostate cancer (mHSPC),
improved prognosis has been reported with the introduction of
novel androgen receptor signaling inhibitors (ARSI) and chemotherapy, particularly docetaxel. However, while some studies
suggest potential benefits of triplet therapy, there are also reports
indicating that adding docetaxel to doublet therapy with ARSI
and androgen deprivation therapy (ADT) may not improve overall treatment outcomes [1, 2].
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
大类|4 区医学
小类|4 区泌尿学与肾脏学
最新[2025]版：
大类|4 区医学
小类|4 区泌尿学与肾脏学
第一作者：
第一作者机构：[1]Department of Urology, Institute of Science Tokyo, Tokyo, Japan.[2]Department of Urology, Zigong Fourth People's Hospital, Zigong, Sichuan, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Chen Wei,Yoshida Soichiro,Fujii Yasuhisa.Is Docetaxel Essential for Darolutamide-Based Metastatic Hormone-Sensitive Prostate Cancer Therapy?[J].International Journal Of Urology : Official Journal Of The Japanese Urological Association.2025,doi:10.1111/iju.70072.
APA：
Chen Wei,Yoshida Soichiro&Fujii Yasuhisa.(2025).Is Docetaxel Essential for Darolutamide-Based Metastatic Hormone-Sensitive Prostate Cancer Therapy?.International Journal Of Urology : Official Journal Of The Japanese Urological Association,,
MLA：
Chen Wei,et al."Is Docetaxel Essential for Darolutamide-Based Metastatic Hormone-Sensitive Prostate Cancer Therapy?".International Journal Of Urology : Official Journal Of The Japanese Urological Association .(2025)
